Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vor Biopharma Q3 Loss Narrows

Vor Biopharma Q3 Loss Narrows

MT newswireMT newswire2026/10/30 12:42
08:42 AM EDT, 10/30/2026 (MT Newswires) -- Vor Biopharma (VOR) reported a Q3 loss Friday of $86.7 million, narrowing from a loss of $812.7 million a year earlier. Analysts polled by FactSet expected a loss of $48.2 million. As of Sept. 30, the company said it had $481.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations into early 2029.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic has not yet gone public, but 20 leveraged ETFs have already "jumped the gun"

More than 20 leveraged ETF products focused on Anthropic have already completed early filings in the United States prior to listing, with issuers including Direxion, ProShares, and GraniteShares. Competition is intensifying even before the IPO. First-mover advantage is critical; after SpaceX went public, out of 14 related products, only one reached assets under management of over 100 million USD. The "winner-takes-all" effect is driving issuers to rush to market.

华尔街见闻•2026/11/19 01:12
Anthropic has not yet gone public, but 20 leveraged ETFs have already "jumped the gun"